WHO WE ARE
We share a passion for helping our clients grow
For over 40 years, Kx Advisors (operating as the healthcare consulting practice of Kaiser Associates) have provided advisory services to help leading pharmaceutical, biotechnology and medical technology companies fully capitalize on product opportunities, navigate the environment with greater certainty, and maximize the lifetime commercial value of their portfolios.
We do this by conducting comprehensive primary research and data-driven analysis at all stages of the product lifecycle to inform the decision making of sales, marketing and strategy executives.
The Kx approach establishes the required fact base to vet critical decisions and brings together data from disparate sources to develop holistic strategies.
With offices in Washington D.C, London, and Boston, Kx Advisors possesses the unique ability to generate global insights from physicians, thought leaders, patients, competitors, partners, regulators, suppliers, and payers.
The Kx approach establishes the required fact base to vet critical decisions and brings together data from disparate sources to develop holistic strategies.
How we’re different
We focus on growth strategy
Unlike large consulting firms who toggle between operational work and heterogenous strategy work, we live and breathe healthcare growth strategy. As a result, we have developed deep expertise in exploring new business models, evaluating new technologies, entering new markets, and capitalizing on new policies. Our focus drives results.
We prioritize pragmatism and clarity
We pride ourselves on developing elegant solutions to complex problems. We share a passion for helping our clients devise winning strategies and gain organization buy-in through clear business cases, impactful storytelling, and actionable recommendations.
We believe in data-driven decision making
Insight generation and quantitative rigor define our consulting approach. We are experts at designing research to inform quantitative models, developing forecasts in emerging and innovative markets, and quantifying what is difficult to quantify.
We deliver a first-class client experience
We value collaboration and partnership above all else and design our engagements to follow a highly iterative process. We start fast, deliver against compressed timelines and respond to changing client needs with agility. Our senior leaders remain actively involved throughout our engagements and set a high standard of excellence.
Leadership Team
Dan O’Neill
Managing PartnerDan O’Neill is a Managing Partner at Kx Advisors. He is based in Washington, DC.
Dan has significant experience developing commercial growth strategies for leading Pharmaceutical, Medical Device and Health Technology clients. Since joining Kaiser Associates in 2006, Dan has developed expertise across all major therapeutic areas and project types. Specific emphases include commercial due diligence, strategic marketing, product launch planning, market opportunity assessments, and competitive strategy. He has expertise in integrated research and quantitative modeling techniques related to product pricing and forecasting.
Dan started his career in finance and banking where he developed his quantitative background. Dan holds an MBA from the McDonough School of Business at Georgetown University and a BBA from the University of Kentucky.
Bob Serrano
Managing PartnerBob Serrano is a Managing Partner at Kx Advisors. He is based in Washington, DC.
Bob has nearly 20 years of experience in the healthcare industry, specializing in specialty pharma, interventional medicine, and clinical diagnostics. Bob has extensive expertise in building growth strategies across therapeutic areas including oncology, dermatology, neurology, immunology, and cardiology. Prior to Kaiser Associates and Kx Advisors, Bob held several strategy and sales roles at Abbott (now AbbVie), and led North American laboratory marketing for QIAGEN’s molecular diagnostics business.
Bob earned an MBA from the Kellogg School of Management at Northwestern University, and a Master’s in Health Administration and a BS in Nutritional Science from Cornell University.
Sean Vander Linde
PartnerSean Vander Linde is a Partner at Kx Advisors and is based in Washington, DC.
Sean brings deep experience leading engagements across the healthcare value chain with provider, health IT, biopharma, and medical device companies. His expertise includes advising clients on corporate strategy, market opportunity assessments, new product launch, and commercial due diligence. Prior to joining Kaiser Associates and Kx Advisors, he worked at L.E.K. Consulting and PwC focusing on healthcare.
Sean holds an MBA from the Tuck School of Business at Dartmouth and a BA in Political Science from the University of North Carolina at Chapel Hill.
Nikil Kumar
PartnerNikil Kumar is a Partner at Kx Advisors who is based in New York.
Nikil has partnered with a wide array of pharmaceutical and biotech clients on developing powerful and pragmatic growth strategies. He has worked across many therapeutic areas with a specialized focus on oncology in both solid and hematologic malignancies. His work primarily focuses on market opportunity assessments, portfolio strategy, product launch strategy, and marketing strategy.
Prior to joining Kx Advisors, Nikil held strategy consulting roles at BGB Group and Omnicom Health Group. Nikil holds a B.S. in Neuroscience from Stony Brook University.
Mudita Vaish
Partner
Sonya Jakawich
Senior Vice PresidentSonya is a Senior Vice President at Kx Advisors, based in New York City.
With over 13 years of experience in life sciences strategic advisory, Sonya partners with clients across the healthcare ecosystem to shape early product and portfolio strategies.
Her expertise spans key therapeutic areas such as Oncology, Obesity/T2D, and Immunology. She brings a deep understanding of the scientific and commercial landscape, having worked closely with cross-functional teams at global pharmaceutical companies, emerging biotechs, and venture capital/private equity firms.
Before joining Kx, Sonya held roles at Pfizer and Trinity Life Sciences. She earned her Ph.D. in Neuroscience from the University of Michigan and a B.S. in Cellular and Molecular Biology from the University of Washington.
Outside of work, Sonya is an avid animal advocate, fitness enthusiast, and culinary explorer who enjoys discovering new restaurants and catching the latest shows around the city.
Alejandro Altaras
Senior Vice PresidentAlejandro Altaras is a Senior Vice President with Kx Advisors. He is based in Boston, MA.
Alejandro has over 10 years of experience consulting for the life sciences industry. He specializes in commercialization and go-to-market strategies for pharmaceuticals. He has extensive expertise developing customer segmentation strategies, designing go-to-market models, and supporting clients as they prepare to launch assets.
Prior Kx Advisors, Alejandro spent over 10 years with ZS Associates, helping clients with go-to-market, forecasting, sales analytics, and sales operations issues. He has also consulted with Accenture, OC&C Strategy Consultants, and Oliver Wyman.
Alejandro earned an MBA from the MIT Sloan School of Management, a Masters in Industrial & Operations Engineering from the University of Michigan, and a BSE in Industrial Engineering from the Universidad Simon Bolivar in Caracas, Venezuela.
Masha Dumanis
Senior Vice PresidentMasha Dumanis is a Senior Vice President at Kx Advisors and is based at the firm’s Boston office.
Masha is a recognized thought leader and sought out advisor in the MedTech and Digital Health sector, even more so in her areas of deep expertise: Musculoskeletal (MSK) and Women’s Health.
Masha brings to Kx and its clients over 13 years of experience in healthcare strategy consulting supporting companies with growth strategy, Go-To-Market strategy, commercial due diligence, market access, M&A and corporate strategy.
Masha prides herself on establishing deep relationships with clients to understand their needs and to guide them with data driven decision making.
Prior to joining Kx, Masha worked as a Vice President at Health Advances, a Parexel consulting company and served as leader of its MSK practice area. Masha holds an A.B. cum laude in Human Evolutionary Biology from Harvard College. She also serves as Senior Advisor to the Journal of Orthopaedic Experience & Innovation (JOEI).
Chris Waybill
Senior Vice PresidentChris Waybill is a Senior Vice President based in the San Francisco Bay Area with over 10 years of experience in strategy consulting.
Since joining Kx in 2016, he has led more than 200 growth strategy engagements spanning corporate strategy, BD&L and M&A, product development, and commercial/GTM strategy—with particular emphasis on brand planning and launch strategy. He has advised leading pharmaceutical and biotechnology companies across CNS, dermatology, immunology, and medical aesthetics, and medical device firms across interventional technologies, diagnostics, and connected wearables.
Chris co-leads Kx’s CNS Practice, where he brings specialized expertise in cognitive disorders, neuropsychiatric diseases, pain, movement disorders, and cerebrovascular conditions. Chris also partners closely with BGB Group’s Innovation & Intelligence (IxI) team, helping clients apply AI, behavioral science, and advanced analytics to drive strategic clarity and competitive edge. He holds a B.S.E. in Mechanical Engineering & Materials Science from Duke University.
David Geschwind
Vice PresidentDavid is a Vice President at Kx Advisors and is based in San Francisco, CA.
David has extensive experience leading growth strategy engagements for Pharma, Biotech, MedTech, and Digital Health clients. Specifically, he advises clients on product launch strategy, commercial operations, financial modelling, forecasting, commercial due diligence, pricing, and market access.
David’s therapeutic areas of expertise include interventional medicine, medical aesthetics, eye care, dermatology, and oncology.
David holds a B.A. in Computer Science and Economics from Swarthmore College.
Chloe Lok
Vice PresidentChloe is a Vice President with over 10 years of experience in the healthcare industry, leading engagements across pharma, biotech, and digital health. She has deep expertise in rare diseases, immunology, and haematology, and has also worked extensively in respiratory, oncology, psychiatry, and dermatology.
Chloe works closely with global clients to shape asset and portfolio strategy, drive launch planning, and navigate complex commercial and clinical landscapes. She brings robust experience in qualitative and quantitative research, strategic marketing, patient journey mapping, and forecasting. Known for her thoughtful approach and ability to translate insights into clear, actionable strategy, she is passionate about helping teams unlock the full potential of their innovations to improve patient outcomes.
Chloe holds an MSc in Management from Imperial College Business School and a BSc in Biochemistry from the University of Reading.
Allie Fascione-Hutchins
PrincipalAllie partners with clients to develop both upstream and downstream growth strategies across all of Kx’s key sectors and therapeutic areas. Specifically, she collaborates with biopharmaceutical, medical device, and diagnostic companies, in therapeutic areas including dermatology, critical care, and cardiology. Functionally, Allie’s expertise encompasses market entry strategy, commercial due diligence, opportunity forecasting, long-term franchise planning, and commercial benchmarking. Her work integrates data analytics, competitive intelligence, and voice-of-customer research to create simple and meaningful solutions to complex problems.
Prior to Kx, Allie worked with companies in the financial services and consumer goods industries as a strategy consultant. Allie holds a B.S. with Honors in Economics, with a Mathematical Economics concentration from Haverford College.
Jenny Knauss
PrincipalJenny has nearly 10 years of experience in the healthcare industry, working across consulting and communications. She brings deep expertise in oncology, both solid tumors and hematological malignancies, and has partnered with Medical Affairs and Commercial clients to inform strategy from early clinical development and landscape analyses through launch planning, brand strategy, and lifecycle management.
Prior to joining Kx, Jenny worked in healthcare consulting at McKinsey & Company and medical communications at BGB Group. She holds a PhD in Cell and Developmental Biology from Weill Cornell Medicine Graduate School of Medical Sciences.
Women@Kx
Empowering Our Employees At Every Step
Gender diversity is a keystone in Kx’s inclusive company culture. Our firm supports women at each stage of their career, from new employees to established senior leaders.
Established in 2020, Women@Kx is a monthly meet-up group to provide our consultants with the tools they need to succeed while advancing gender equality in a fast-paced consulting environment. Led by Senior Vice President Masha Dumanis, the group focuses on empowering women and allies by offering opportunities for professional development, mentoring, and building meaningful networks.
Awards & Recognition
Celebrating Our Team
Kx works each day to empower our clients and our people to change the world. We’re proud to be publicly recognized for our efforts, especially as a leader for top talent.
What’s happening at Kx Advisors
Kx Advisors
Locations
Our global reach
Kx New York
Penn1, 250 West 34th Street3rd Floor, Suite 302
New York, NY 10119
Kx Washington, D.C.
1615 L Street, NW, Suite 1300Washington, DC 20036
Kx London
Kx Advisors131 Finsbury Pavement
London, EC2A 1NT
Kx Boston
100 Summer Street, Suite 1600Boston, MA, 02110